Ponatinib PACE Trial Infographic

A few months ago, the FDA approved Ponatinib for patients with chronic, accelerated, or blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The accelerated approval was based on results from the PACE (Ponatinib Ph+ ALL and CML Evaluation) trial, presented at the American Society of Hematology’s annual meeting.

The primary end point responses represent a major cytogenetic response in chronic phase CML and a major hematologic response in accelerated phase CML/Ph+ ALL. The following infographic represents a visual interpretation of the data presented: